Skip to main content

PerkinElmer Value Stock - Dividend - Research Selection

Perkinelmer

ISIN: US7140461093 , WKN: 850943

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!

How our site works ...

✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month 
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment develops and offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries; and laboratory services. In addition, this segment offers a suite of solutions comprising reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market. The Diagnostics segment provides instruments, reagents, and software test and screen products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used in diagnosing genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in applications covering oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. has a collaboration agreement with Helix. The company was founded in 1931 and is headquartered in Waltham, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Revvity (RVTY), What Is Drawing Fresh Attention Now?

2026-10-15
Revvity (RVTY) is back on investor calendars after announcing third quarter 2026 results are due on 3 November, with earnings per share expected to be higher and fresh conference appearances scheduled soon after. Revvity’s share price has surged over the past quarter, with a 30 day share price return of 18.4% and a 90 day gain of 36.2%. The 1 year total shareholder return of 65.6% contrasts with a weaker 5 year total shareholder return that is still down 12.8%, suggesting momentum has...

How To Invest In AI Drug Discovery

2026-10-15
While AI can design prospective drug molecules in seconds, validating whether they work still depends on slow physical wet-lab testing and custom testing tools.

Revvity (RVTY) Stock Could Be 12% Stretched On Cash Flow

2026-10-15
Revvity has delivered a strong share price run over the past year, and the key issue now is whether that market enthusiasm lines up with the cash the business can realistically generate. With the stock recently closing at US$152.12, investors are asking if the current tag fairly reflects the company’s underlying cash flows or if expectations are stretching ahead of what the business can support. Over the past 12 months, Revvity has returned 65.6%, which puts real weight on the question of...

Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings

2026-10-14
DGX heads into Q3 earnings with expected revenue and EPS growth, fueled by strong clinical demand, advanced diagnostics and operational efficiencies.

3 Hyped Up Stocks We Think Twice About

2026-10-14
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.

Here's How Much $100 Invested In Revvity 15 Years Ago Would Be Worth Today

2026-10-13
Revvity (NYSE:RVTY) has outperformed the market over the past 15 years by 1.91% on an annualized basis producing an average annual return of 15.11%. Currently, Revvity has a market capitalization of $17.36 billion.

Thermo Fisher to Report Q3 Earnings: What's in the Cards?

2026-10-13
TMO gears up for Q3 earnings, with revenue and EPS growth expected amid strong bioproduction demand, product innovations and clinical research strength.

Revvity to Present at Upcoming Investor Conferences

2026-10-13
WALTHAM, Mass., October 13, 2026--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences:

TD Cowen Maintains Buy on Revvity, Raises Price Target to $175

2026-10-13
TD Cowen analyst Dan Brennan maintains Revvity (NYSE:RVTY) with a Buy and raises the price target from $130 to $175.

Which S&P500 stocks are gapping on Thursday?

2026-10-08
Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Thursday and stay ahead of the market trends.